Disruption of this enhancer–promoter interaction through genetic or epigenetic means can reduce HER2 expression and inhibit tumor growth, highlighting the therapeutic potential of targeting enhancer activity in HER2-enriched BCs. Here, ERBB2 is linked to neoplasm.